Myriad Genetics Q1 Loss Widens

May 05, 2026 — 05:48 pm EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Myriad Genetics, Inc. (MYGN) on Tuesday reported first-quarter results with revenue rising slightly from last year, while losses widened compared to the prior period.

The company posted revenue of $200.4 million for the three months ended March 31, 2026, up from $195.9 million a year earlier. Net loss widened to $34.1 million from a near break-even loss of $0.1 million in the prior-year quarter. Loss per share was $0.36 for the quarter, while weighted average shares outstanding stood at 93.7 million.

Operating loss came in at $30.7 million, up from $29.0 million last year, as total operating expenses increased to $168.3 million from $163.2 million. The higher expenses were driven in part by research and development costs of $27.1 million and sales and marketing expenses of $73.6 million.

MYGN is currently trading after hours at $4.47, down $0.56 or 11.13 percent on the Nasdaq.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Myriad Genetics Q1 Loss Widens

Tags

Latest Articles